Medpace Holdings, Inc.
Case Overview
55 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 06/08/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Medpace Holdings, Inc. |
| Court: | Court: Southern District of Ohio |
| Case Number: | Case Number: 1:26cv00346 |
| Class Period: | Class Period: 4/22/2025 - 02/09/2026 |
| Ticker: | Ticker: MEDP |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ:MEDP) securities during the period of April 22, 2025 through February 9, 2026, inclusive (“the Class Period”).
The lawsuit alleges that the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. The Company continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio.
On February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1. 15. On this news, the price of Medpace shares declined by $84.30 per share, or approximately 16%, from $530.35 per share on February 9, 2026 to close at $446.05 on February 10, 2026.
The lawsuit alleges that the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the true state of Medpace's backlog cancellation rate. The Company continuously touted "well behaved" cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio.
On February 9, 2026, Medpace issued a press release announcing the Company's fourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1. 15. On this news, the price of Medpace shares declined by $84.30 per share, or approximately 16%, from $530.35 per share on February 9, 2026 to close at $446.05 on February 10, 2026.